vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and RANGE RESOURCES CORP (RRC). Click either name above to swap in a different company.
RANGE RESOURCES CORP is the larger business by last-quarter revenue ($786.9M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). RANGE RESOURCES CORP runs the higher net margin — 22.8% vs 19.1%, a 3.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 18.0%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 14.6%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Range Resources Corporation is a natural gas exploration and production company, the headquartered is in Fort Worth, Texas. It operates in the Marcellus Formation, where it is the largest land owners.
MEDP vs RRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $786.9M |
| Net Profit | $135.1M | $179.1M |
| Gross Margin | — | 94.5% |
| Operating Margin | 21.6% | — |
| Net Margin | 19.1% | 22.8% |
| Revenue YoY | 32.0% | 18.0% |
| Net Profit YoY | 15.5% | 88.8% |
| EPS (diluted) | $4.65 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $786.9M | ||
| Q3 25 | $659.9M | $655.3M | ||
| Q2 25 | $603.3M | $699.6M | ||
| Q1 25 | $558.6M | $846.3M | ||
| Q4 24 | $536.6M | $667.0M | ||
| Q3 24 | $533.3M | $567.9M | ||
| Q2 24 | $528.1M | $513.2M | ||
| Q1 24 | $511.0M | $598.8M |
| Q4 25 | $135.1M | $179.1M | ||
| Q3 25 | $111.1M | $144.3M | ||
| Q2 25 | $90.3M | $237.6M | ||
| Q1 25 | $114.6M | $97.1M | ||
| Q4 24 | $117.0M | $94.8M | ||
| Q3 24 | $96.4M | $50.7M | ||
| Q2 24 | $88.4M | $28.7M | ||
| Q1 24 | $102.6M | $92.1M |
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 20.9% | — | ||
| Q1 25 | 20.3% | — | ||
| Q4 24 | 23.4% | — | ||
| Q3 24 | 21.1% | — | ||
| Q2 24 | 19.9% | — | ||
| Q1 24 | 20.4% | — |
| Q4 25 | 19.1% | 22.8% | ||
| Q3 25 | 16.8% | 22.0% | ||
| Q2 25 | 15.0% | 34.0% | ||
| Q1 25 | 20.5% | 11.5% | ||
| Q4 24 | 21.8% | 14.2% | ||
| Q3 24 | 18.1% | 8.9% | ||
| Q2 24 | 16.7% | 5.6% | ||
| Q1 24 | 20.1% | 15.4% |
| Q4 25 | $4.65 | $0.75 | ||
| Q3 25 | $3.86 | $0.60 | ||
| Q2 25 | $3.10 | $0.99 | ||
| Q1 25 | $3.67 | $0.40 | ||
| Q4 24 | $3.67 | $0.38 | ||
| Q3 24 | $3.01 | $0.21 | ||
| Q2 24 | $2.75 | $0.12 | ||
| Q1 24 | $3.20 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $204.0K |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $459.1M | $4.3B |
| Total Assets | $2.0B | $7.4B |
| Debt / EquityLower = less leverage | — | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $204.0K | ||
| Q3 25 | $285.4M | $175.0K | ||
| Q2 25 | $46.3M | $134.0K | ||
| Q1 25 | $441.4M | $344.6M | ||
| Q4 24 | $669.4M | $304.5M | ||
| Q3 24 | $656.9M | $277.4M | ||
| Q2 24 | $510.9M | $251.1M | ||
| Q1 24 | $407.0M | $343.1M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | $459.1M | $4.3B | ||
| Q3 25 | $293.6M | $4.2B | ||
| Q2 25 | $172.4M | $4.1B | ||
| Q1 25 | $593.6M | $3.9B | ||
| Q4 24 | $825.5M | $3.9B | ||
| Q3 24 | $881.4M | $3.9B | ||
| Q2 24 | $763.6M | $3.9B | ||
| Q1 24 | $671.5M | $3.8B |
| Q4 25 | $2.0B | $7.4B | ||
| Q3 25 | $1.8B | $7.2B | ||
| Q2 25 | $1.6B | $7.1B | ||
| Q1 25 | $1.9B | $7.4B | ||
| Q4 24 | $2.1B | $7.3B | ||
| Q3 24 | $2.1B | $7.2B | ||
| Q2 24 | $1.9B | $7.3B | ||
| Q1 24 | $1.8B | $7.4B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $257.5M |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $257.5M | ||
| Q3 25 | $246.2M | $247.5M | ||
| Q2 25 | $148.5M | $336.2M | ||
| Q1 25 | $125.8M | $330.1M | ||
| Q4 24 | $190.7M | $217.9M | ||
| Q3 24 | $149.1M | $245.9M | ||
| Q2 24 | $116.4M | $148.8M | ||
| Q1 24 | $152.7M | $331.9M |
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | — | ||
| Q1 24 | $147.2M | — |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 28.8% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.43× | 1.44× | ||
| Q3 25 | 2.22× | 1.72× | ||
| Q2 25 | 1.65× | 1.42× | ||
| Q1 25 | 1.10× | 3.40× | ||
| Q4 24 | 1.63× | 2.30× | ||
| Q3 24 | 1.55× | 4.85× | ||
| Q2 24 | 1.32× | 5.18× | ||
| Q1 24 | 1.49× | 3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
